Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: faldaprevir
Drug: Microgynon®
Drug: BI 207127

First Posted Date: 2013-09-13

Last Posted Date: 2016-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01941615

Locations: 🇩🇪
1241.31.2 Boehringer Ingelheim Investigational Site, Mannheim, Germany

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 860585
Drug: exemestane
Drug: paclitaxel

First Posted Date: 2013-09-10

Last Posted Date: 2019-01-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 90

Registration Number: NCT01938846

Locations: 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇮🇹
Azienda Ospedaliera di Parma, Parma, Italy

and more 1 locations

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation
Drug: Indacterol 300 µg
Drug: Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule
Drug: Indacterol 150 µg

First Posted Date: 2013-09-09

Last Posted Date: 2018-07-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 645

Registration Number: NCT01937390

Locations: 🇩🇪
CTMS MIGRATION CENTER representing all obvious CTMS Dummy Sites, Ingelheim am Rhein, Germany

GLORIA-AF Registry Program (Phase II/III)

Completed

Conditions: Stroke
Atrial Fibrillation

First Posted Date: 2013-09-09

Last Posted Date: 2021-02-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT01937377

Locations: 🇨🇭
Kantonsspital St.Gallen, St. Gallen, Switzerland
🇨🇭
CHUV - Centre hospitalier universitaire vaudois, Lausanne, Switzerland
🇨🇭
University Hospital Basel, Basel, Switzerland

and more 2 locations

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2013-08-29

Last Posted Date: 2018-11-14

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01931306

Locations: 🇰🇷
The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon, Korea, Republic of
🇰🇷
Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

and more 5 locations

Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

Phase 3

Completed

Conditions: Tooth Diseases
Pain, Postoperative

Interventions: Drug: ibuprofen + caffeine
Drug: ibuprofen
Drug: placebo
Drug: caffeine

First Posted Date: 2013-08-27

Last Posted Date: 2016-11-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 562

Registration Number: NCT01929031

Locations: 🇺🇸
1335.1.202 Boehringer Ingelheim Investigational Site, Salt Lake City, Utah, United States

Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain

Phase 3

Completed

Conditions: Intestinal Diseases

Interventions: Drug: Buscopan® (hyoscine butylbromide)
Drug: 654-II (anisodamine)

First Posted Date: 2013-08-27

Last Posted Date: 2016-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 299

Registration Number: NCT01929044

Locations: 🇨🇳
202.848.86013 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳
202.848.86020 Boehringer Ingelheim Investigational Site, Changsha, China
🇨🇳
202.848.86007 Boehringer Ingelheim Investigational Site, Chongqing, China

and more 17 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773 Placebo
Drug: BI 10773

First Posted Date: 2013-08-16

Last Posted Date: 2014-07-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01924767

Locations: 🇩🇪
1245.2.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 113608
Drug: Placebo

First Posted Date: 2013-08-14

Last Posted Date: 2017-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 98

Registration Number: NCT01922349

Locations: 🇰🇷
1314.9.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 655064
Drug: Placebo

First Posted Date: 2013-08-07

Last Posted Date: 2023-08-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT01917916

Locations: 🇰🇷
1293.8.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇯🇵
1293.8.8101 Boehringer Ingelheim Investigational Site, Sumida-ku,Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy